Shanghai Pharmaceuticals: The Approval Number for Tigrelor Tablets Obtained from the US FDA

Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has received a notification from the US Food and Drug Administration that its abbreviated new drug application for Ticagrelor Tablets has been finally approved for market. Ticagrelor Tablets are used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndrome. The original research was developed by AstraZeneca and was launched in the United States in 2011. As of the date of this announcement, the company has invested approximately RMB 9.6713 million in research and development expenses for this drug.